Thrombolytic Therapy Targeting Alpha 2-Antiplasmin

Acquired alpha 2 antiplasmin deficiency in glomerular proteinuria.

Gene targeting in hemostasis. Alpha2-antiplasmin.

Apha2-antiplasmin (AP), the main physiological plasmin inhibitor in mammalian plasma, is a 70 kDa single chain serpin (serine proteinase inhibitor) with reactive site peptide bond Arg-Met. It inhibits plasmin very rapidly (second-order inhibition rate constant of = 2 x 107 M-1.s-1) following formation of an inactive 1:1 stoichiometric complex. The high reaction rate requires the presence of a f...

Thrombolytic therapy.

Thrombolytic therapy, which involves the administration of agents designed to increase fibrinolytic capacity, has been utilized in respiratory medicine for more than 50 years. A variety of agents have been used to effect thrombolysis, including urokinase plasminogen activator (uPA) and streptokinase. Tissue plasminogen activator (tPA) has also been used to effect thrombolysis. Both uPA and tPA ...

Thrombolytic Therapy.

The purpose of this communication is to review briefly the agents available at the present time for use in thrombolytic therapy and to indicate why we believe that at the present time streptokinase is the only suitable agent for extended clinical trial. An account will then be given of the use of streptokinase administered by local perfusion in the treatment of peripheral arterial occlusion and...

[Thrombolytic therapy].